E. Gangolli

发表

364 First-in-human phase 1 study of MLN2480, an investigational oral pan-RAF kinase inhibitor, in patients (pts) with relapsed or refractory solid tumors, including BRAF/NRAS-mutant melanoma

J. Larkin, R. Plummer, M. Kneissl, 2014 .

Deficient Gene Expression in Protein Kinase Inhibitor α Null Mutant Mice

M. Uhler, R. Idzerda, G. McKnight, 2000, Molecular and Cellular Biology.

Deﬁcient Gene Expression in Protein Kinase Inhibitor a Null Mutant Mice

M. Uhler, R. Idzerda, G. McKnight, 2000 .

Reproductive Function in Protein Kinase Inhibitor-Deficient Mice

R. Idzerda, E. Gangolli, Mouna Belyamani, 2001, Molecular and Cellular Biology.

Dose-Escalation Trial of the Oral Investigational Hedgehog Signaling Pathway Inhibitor TAK-441 in Patients with Advanced Solid Tumors

M. Hidalgo, M. Borad, D. Ryan, 2015 .

Phase I Dose-Escalation Trial of the Oral Investigational Hedgehog Signaling Pathway Inhibitor TAK-441 in Patients with Advanced Solid Tumors

M. Hidalgo, M. Borad, D. Ryan, 2014, Clinical Cancer Research.

Abstract 445: Genomic characteristics and response to rucaparib and enzalutamide in the phase 1b RAMP study of metastatic castration-resistant prostate cancer (mCRPC) patients

C. Ryan, V. Assikis, Jim J. Xiao, 2021, Clinical research.

Rucaparib plus enzalutamide in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Pharmacokinetics (PK) and safety data from the phase Ib RAMP study.

D. Morris, C. Ryan, V. Assikis, 2021 .

A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors

R. Neuwirth, J. Sosman, A. Ribas, 2016, Investigational New Drugs.

Abstract C252: A phase 1, dose-escalation study of MLN0128, an investigational oral mammalian target of rapamycin complex 1/2 (mTORC1/2) catalytic inhibitor, in patients (pts) with advanced non-hematologic malignancies.

R. Neuwirth, J. Tabernero, S. Jalal, 2013 .

317 Characterization of pharmacokinetics, pharmacodynamics, tolerability and clinical activity in phase I studies of the novel allosteric tyrosine kinase 2 (TYK2) inhibitor NDI-034858

J. McElwee, V. Hosagrahara, S. Carreiro, 2022, Journal of Investigative Dermatology.

Mechanisms of Acquired Resistance to Savolitinib, a Selective MET Inhibitor in MET-Amplified Gastric Cancer

J. Barrett, S. Park, Kyoung-Mee Kim, 2020, JCO precision oncology.

Neurotransmitters activate the human estrogen receptor in a neuroblastoma cell line

B. O’Malley, O. Conneely, E. Gangolli, 1997, The Journal of Steroid Biochemistry and Molecular Biology.

Phase I, dose-escalation study of the investigational drug TAK-733, an oral MEK inhibitor, in patients (pts) with advanced solid tumors.

R. Neuwirth, J. Sosman, A. Ribas, 2013 .

Combination of Docetaxel Plus Savolitinib in Refractory Cancer Patients: A Report on Phase I Trial

Joon-Oh Park, S. Park, Kyoung-Mee Kim, 2019, Translational oncology.

Antitumor Activity of the MEK Inhibitor TAK-733 against Melanoma Cell Lines and Patient-Derived Tumor Explants

H. Selby, A. Tan, P. Vincent, 2014, Molecular Cancer Therapeutics.

A Phase I/II Study of BHQ880, a Novel Osteoblat Activating, Anti-DKK1 Human Monoclonal Antibody, in Relapsed and Refractory Multiple Myeloma (MM) Patients Treated with Zoledronic Acid (Zol) and Anti-Myeloma Therapy (MM Tx).

N. Munshi, A. Dzik-Jurasz, F. Giles, 2009 .

Phase 1 trial of the adenosine A2A receptor antagonist inupadenant (EOS-850): Update on tolerability, and antitumor activity potentially associated with the expression of the A2A receptor within the tumor.

J. Machiels, L. Buisseret, N. Wald, 2021 .

Clinical pharmacokinetics (PK) and translational PK-pharmacodynamic (PD) modeling and simulation to predict antitumor response of various dosing schedules to guide the selection of a recommended phase II dose (RP2D) and schedule for the investigational agent MLN0128.

K. Venkatakrishnan, S. Jalal, J. Infante, 2013 .

Antitumor Activity of the MEK Inhibitor TAK-733 against Melanoma Cell Lines and Patient-Derived Tumor Explants

H. Selby, T. Pitts, Robyn Fabrey, 2014, Molecular Cancer Therapeutics.

MLN2480, an investigational oral pan-RAF kinase inhibitor, in patients (pts) with relapsed or refractory solid tumors: Phase I study.

R. Neuwirth, M. Kneissl, D. Rasco, 2013 .